| Year |
Citation |
Score |
| 2024 |
Hu B, Wiesehöfer M, de Miguel FJ, Liu Z, Chan LH, Choi J, Melnick MA, Arnal-Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, ... ... Politi K, et al. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Research. PMID 38359163 DOI: 10.1158/0008-5472.CAN-23-0438 |
0.489 |
|
| 2024 |
Kuhlmann-Hogan A, Cordes T, Xu Z, Kuna RS, Traina KA, Robles-Oteíza C, Ayeni D, Kwong EM, Levy S, Globig AM, Nobari MM, Cheng GZ, Leibel SL, Homer RJ, Shaw RJ, ... ... Politi K, et al. EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth. Cancer Discovery. OF1-OF22. PMID 38270272 DOI: 10.1158/2159-8290.CD-23-0434 |
0.413 |
|
| 2024 |
Kuhlmann-Hogan A, Cordes T, Xu Z, Kuna RS, Traina KA, Robles-Oteiza C, Ayeni D, Kwong EM, Levy S, Globig AM, Nobari MM, Cheng GZ, Leibel SL, Homer RJ, Shaw RJ, ... ... Politi K, et al. EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth. Cancer Discovery. PMID 38241033 DOI: 10.1158/2159-8290.CD-23-0434 |
0.413 |
|
| 2023 |
Blair LM, Juan JM, Sebastian L, Tran VB, Nie W, Wall GD, Gerceker M, Lai IK, Apilado EA, Grenot G, Amar D, Foggetti G, Do Carmo M, Ugur Z, Deng D, ... ... Politi K, et al. Oncogenic context shapes the fitness landscape of tumor suppression. Nature Communications. 14: 6422. PMID 37828026 DOI: 10.1038/s41467-023-42156-y |
0.358 |
|
| 2023 |
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, et al. Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37806385 DOI: 10.1016/j.jtho.2023.10.001 |
0.4 |
|
| 2023 |
de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, ... ... Politi KA, et al. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. PMID 37541244 DOI: 10.1016/j.ccell.2023.07.005 |
0.445 |
|
| 2023 |
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solórzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, ... ... Politi K, et al. PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer Research. PMID 37311042 DOI: 10.1158/0008-5472.CAN-22-3023 |
0.399 |
|
| 2023 |
Kuhlmann-Hogan A, Cordes T, Xu Z, Traina KA, Robles-Oteíza C, Ayeni D, Kwong EM, Levy SR, Nobari M, Cheng GZ, Shaw R, Leibel SL, Metallo CM, Politi K, Kaech SM. EGFR lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth. Biorxiv : the Preprint Server For Biology. PMID 37131637 DOI: 10.1101/2023.04.15.536974 |
0.417 |
|
| 2023 |
Mart Nez-Terroba E, de Miguel FJ, Li V, Robles-Oteiza C, Politi K, Zamudio JR, Dimitrova N. Overexpressed Drives Metastasis through Inflammatory Reprogramming of Lung Adenocarcinoma Microenvironment. Biorxiv : the Preprint Server For Biology. PMID 36993368 DOI: 10.1101/2023.03.20.533534 |
0.35 |
|
| 2023 |
Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, ... ... Politi K, et al. Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36913537 DOI: 10.1158/1078-0432.CCR-22-3497 |
0.401 |
|
| 2023 |
Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi IS, Sun J, Politi K, Levantini E, Zhang W, Kobayashi SS, Zhang WC. An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1. British Journal of Cancer. PMID 36810913 DOI: 10.1038/s41416-023-02196-z |
0.322 |
|
| 2022 |
Adua SJ, Arnal-Estapé A, Zhao M, Qi B, Liu ZZ, Kravitz C, Hulme H, Strittmatter N, López-Giráldez F, Chande S, Albert AE, Melnick MA, Hu B, Politi K, Chiang V, et al. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer. Nature Communications. 13: 7690. PMID 36509758 DOI: 10.1038/s41467-022-34889-z |
0.391 |
|
| 2022 |
van Alderwerelt van Rosenburgh IK, Lu DM, Grant MJ, Stayrook SE, Phadke M, Walther Z, Goldberg SB, Politi K, Lemmon MA, Ashtekar KD, Tsutsui Y. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications. 13: 6791. PMID 36357385 DOI: 10.1038/s41467-022-34398-z |
0.431 |
|
| 2022 |
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, ... Politi K, et al. YES1 Is a Druggable Oncogenic Target in SCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 35988891 DOI: 10.1016/j.jtho.2022.08.002 |
0.3 |
|
| 2022 |
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, et al. Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nature Communications. 13: 4640. PMID 35941179 DOI: 10.1038/s41467-022-32459-x |
0.351 |
|
| 2022 |
Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35713632 DOI: 10.1158/1078-0432.CCR-22-0741 |
0.343 |
|
| 2022 |
Foggetti G, Li C, Cai H, Petrov DA, Winslow MM, Politi K. Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment. Molecular & Cellular Oncology. 9: 1994328. PMID 35252550 DOI: 10.1080/23723556.2021.1994328 |
0.451 |
|
| 2022 |
Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, et al. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. Jci Insight. 7. PMID 35132961 DOI: 10.1172/jci.insight.142843 |
0.381 |
|
| 2022 |
Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma. Npj Precision Oncology. 6: 8. PMID 35087143 DOI: 10.1038/s41698-021-00248-2 |
0.338 |
|
| 2021 |
Tripathi BK, Anderman MF, Bhargava D, Boccuzzi L, Qian X, Wang D, Durkin ME, Papageorge AG, de Miguel FJ, Politi K, Walters KJ, Doroshow JH, Lowy DR. Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein. Nature Communications. 12: 6941. PMID 34862367 DOI: 10.1038/s41467-021-26993-3 |
0.316 |
|
| 2021 |
Arnal-Estapé A, Foggetti G, Starrett JH, Nguyen DX, Politi K. Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Cold Spring Harbor Perspectives in Medicine. PMID 34518338 DOI: 10.1101/cshperspect.a037820 |
0.355 |
|
| 2021 |
Robles-Oteiza C, Ayeni D, Levy S, Homer RJ, Kaech SM, Politi K. Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma. Disease Models & Mechanisms. PMID 34494649 DOI: 10.1242/dmm.049072 |
0.466 |
|
| 2021 |
Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini DG, Rashleigh N, Levy S, Homer R, Gettinger SN, ... ... Politi K, et al. Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discovery. PMID 33707235 DOI: 10.1158/2159-8290.CD-20-1385 |
0.522 |
|
| 2020 |
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, et al. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001149. PMID 33021871 DOI: 10.1200/JCO.20.01149 |
0.464 |
|
| 2020 |
Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech S, ... ... Politi K, et al. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Research. PMID 32193290 DOI: 10.1158/0008-5472.Can-19-3819 |
0.567 |
|
| 2020 |
Cardenas JJ, Robles-Oteiza C, Politi K. Assessment of IFNγ responsiveness in patient-derived xenografts. Methods in Enzymology. 631: 415-427. PMID 31948560 DOI: 10.1016/Bs.Mie.2019.10.027 |
0.412 |
|
| 2020 |
Mack PC, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MAC, Walther Z, Hirsch FR, Politi KA, Kelly K, Gandara DR. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal of Clinical Oncology. 38: 9532-9532. DOI: 10.1200/Jco.2020.38.15_Suppl.9532 |
0.453 |
|
| 2020 |
Cai H, Li C, Chew SK, Yousefi M, Foggetti G, Lin W, Rogers ZN, Winters IP, McFarland CD, Politi K, Swanton C, Petrov DA, Winslow MM. Abstract IA26: Multiplexed functional cancer genomics Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Ia26 |
0.342 |
|
| 2020 |
Politi KA. Abstract IA10: Modeling sensitivity and resistance to systemic therapies in lung cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Ia10 |
0.62 |
|
| 2020 |
Hu B, Miguel FJd, Liu Z, Chan L, Melnick MA, Yan Q, Nguyen D, Fan R, Politi K. Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A13 |
0.588 |
|
| 2020 |
Foggetti G, Li C, Cai H, Lin W, Ayeni D, Hastings K, Andrejka L, Maghini D, Homer R, Petrov DA, Winslow MM, Politi K. Abstract 1094: Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo Cancer Research. 80: 1094-1094. DOI: 10.1158/1538-7445.Am2020-1094 |
0.618 |
|
| 2020 |
Starrett JH, Guernet A, Cuomo ME, Poels K, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, ... ... Politi K, et al. Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance
EGFR
Mutations The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00612 |
0.442 |
|
| 2020 |
Starrett J, Guernet A, Cuomo M, Poels K, van Alderwerelt van Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, ... ... Politi K, et al. B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations Journal of Thoracic Oncology. 15: S36. DOI: 10.1016/J.Jtho.2019.12.097 |
0.425 |
|
| 2020 |
de Miguel F, Hu B, Cai W, Sun N, Melnick M, Nguyen D, Xiao A, Politi K. B30 The Role of SMARCA4 as an EGFR-Independent Mechanism of Resistance to Osimertinib Journal of Thoracic Oncology. 15: S35-S36. DOI: 10.1016/J.Jtho.2019.12.095 |
0.395 |
|
| 2020 |
Politi K. IA31 Genetic Contributors to Tumor Progression and Drug Resistance in EGFR Mutant Lung Cancer Journal of Thoracic Oncology. 15: S10. DOI: 10.1016/j.jtho.2019.12.029 |
0.469 |
|
| 2019 |
Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. Journal For Immunotherapy of Cancer. 7: 221. PMID 31416487 DOI: 10.1186/S40425-019-0683-0 |
0.338 |
|
| 2019 |
Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, ... ... Politi K, et al. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. Journal For Immunotherapy of Cancer. 7: 172. PMID 31291990 DOI: 10.1186/S40425-019-0643-8 |
0.584 |
|
| 2019 |
Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31182434 DOI: 10.1158/1078-0432.Ccr-19-0780 |
0.537 |
|
| 2019 |
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, ... ... Politi K, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 131. PMID 31113486 DOI: 10.1186/S40425-019-0602-4 |
0.35 |
|
| 2019 |
Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, ... ... Politi K, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31086949 DOI: 10.1093/Annonc/Mdz141 |
0.551 |
|
| 2019 |
Datar IJ, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki MI, Mejías L, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, ... ... Politi K, et al. Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31053602 DOI: 10.1158/1078-0432.Ccr-18-4142 |
0.439 |
|
| 2019 |
Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. Cell Reports. 27: 1277-1292.e7. PMID 31018140 DOI: 10.1016/J.Celrep.2019.03.085 |
0.313 |
|
| 2019 |
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30824587 DOI: 10.1158/1078-0432.Ccr-18-1538 |
0.449 |
|
| 2018 |
Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications. 9: 3196. PMID 30097571 DOI: 10.1038/S41467-018-05032-8 |
0.415 |
|
| 2018 |
Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, ... ... Politi K, et al. amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. PMID 29875142 DOI: 10.1073/Pnas.1717782115 |
0.642 |
|
| 2018 |
Wilson FH, Politi K. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discovery. 8: 676-678. PMID 29858224 DOI: 10.1158/2159-8290.Cd-18-0368 |
0.432 |
|
| 2018 |
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, ... ... Politi K, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nature Medicine. PMID 29686424 DOI: 10.1038/S41591-018-0007-9 |
0.567 |
|
| 2018 |
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29578107 DOI: 10.1016/J.Jtho.2018.03.008 |
0.435 |
|
| 2018 |
Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29330207 DOI: 10.1158/1078-0432.Ccr-17-1341 |
0.485 |
|
| 2018 |
Stewart T, Truini A, DeVeaux M, Zelterman D, Walther Z, Wurtz A, Gettinger SN, Politi KA, Goldberg SB. Differential outcomes in patients with uncommon EGFR exon 19 mutations. Journal of Clinical Oncology. 36: 9056-9056. DOI: 10.1200/Jco.2018.36.15_Suppl.9056 |
0.416 |
|
| 2018 |
Hastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, ... ... Politi K, et al. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A09 |
0.501 |
|
| 2018 |
Goldberg S, Redman M, Lilenbaum R, Politi K, Stinchcombe T, Horn L, Chen E, Mashru S, Gettinger S, Melnick MA, Miao J, Moon J, Kelly K, Gandara D. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403 Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.290 |
0.495 |
|
| 2017 |
Aisner DL, Sholl LM, Berry L, Rossi M, Chen H, Fujimoto J, Moreira AL, Ramalingam S, Villaruz LC, Otterson GA, Haura EB, Politi K, Glisson BS, Cetnar J, Garon E, et al. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29217530 DOI: 10.1158/1078-0432.Ccr-17-2289 |
0.531 |
|
| 2017 |
Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. Biomed Research International. 2017: 7694202. PMID 29119113 DOI: 10.1155/2017/7694202 |
0.524 |
|
| 2017 |
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, ... ... Politi K, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery. PMID 29025772 DOI: 10.1158/2159-8290.Cd-17-0593 |
0.479 |
|
| 2017 |
Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer (Amsterdam, Netherlands). 109: 1-8. PMID 28577937 DOI: 10.1016/J.Lungcan.2017.04.010 |
0.477 |
|
| 2017 |
Henick BS, Goldberg SB, Narayan A, Rossi C, Rodney S, Kole AJ, Politi KA, Gettinger SN, Herbst RS, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: e20652-e20652. DOI: 10.1200/Jco.2017.35.15_Suppl.E20652 |
0.503 |
|
| 2017 |
Datar I, Mani N, Henick BS, Wurtz A, Kaftan E, Herbst RS, Rimm DL, Gettinger SN, Politi KA, Schalper KA. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E14611 |
0.368 |
|
| 2017 |
Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, Germer S, Jordan E, Wang L, Jungbluth AA, Spraggon L, Lovly CM, Kris MG, Yu HA, Riely GJ, ... ... Politi KA, et al. YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. Journal of Clinical Oncology. 35: 9043-9043. DOI: 10.1200/Jco.2017.35.15_Suppl.9043 |
0.642 |
|
| 2017 |
Goldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N, Lee A, Nemati R, Nath S, Mane S, Deng Y, Sukumar N, Zelterman D, Boffa D, Politi K, et al. Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA Annals of Oncology. 28: v478. DOI: 10.1093/Annonc/Mdx380.043 |
0.467 |
|
| 2017 |
Elamin Y, Robichaux J, Lam V, Tsao A, Lu C, Blumenschein G, Kurie J, Brahmer J, Li S, Chen T, Estrada-Bernal A, Truini A, Nilsson M, Le A, Tan Z, ... ... Politi K, et al. OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC Journal of Thoracic Oncology. 12: S1776. DOI: 10.1016/J.Jtho.2017.09.394 |
0.454 |
|
| 2017 |
Kris M, Aisner D, Sholl L, Berry L, Rossi M, Chen H, Fujimoto J, Moreira A, Ramalingam S, Villaruz L, Otterson G, Haura E, Politi K, Glisson B, Cetnar J, et al. P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor Journal of Thoracic Oncology. 12: S2275. DOI: 10.1016/J.Jtho.2017.09.1633 |
0.466 |
|
| 2017 |
Mack P, Miao J, Banks K, Burich R, Politi K, Raymond V, Dix D, Lanman R, Moon J, Melnick MA, Truini A, Redman M, Goldberg S, Gandara DR, Kelly K. P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1487 |
0.394 |
|
| 2017 |
Hastings K, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Zhao Z, Gaffney S, Iamarino A, Zhao S, Bi M, Goldberg S, Chiang A, Liu Z, Townsend J, ... ... Politi K, et al. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas Journal of Thoracic Oncology. 12: S435. DOI: 10.1016/J.Jtho.2016.11.507 |
0.543 |
|
| 2017 |
Suda K, Rozeboom L, Rivard C, Yu H, Melnick MA, Hinz T, Ellison K, Chan D, Politi K, Heasley L, Mitsudomi T, Hirsch FR. MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer Journal of Thoracic Oncology. 12: S433-S434. DOI: 10.1016/J.Jtho.2016.11.505 |
0.498 |
|
| 2017 |
Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S430-S431. DOI: 10.1016/J.Jtho.2016.11.501 |
0.499 |
|
| 2017 |
Choi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick MA, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, ... ... Politi K, et al. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S1331-S1332. DOI: 10.1016/J.Jtho.2016.11.1884 |
0.456 |
|
| 2017 |
Goldberg S, Moon J, Lilenbaum R, Politi K, Melnick MA, Stinchcombe T, Horn L, Chen E, Miao J, Redman M, Kelly K, Gandara DR. P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403: Topic: EGFR Clinical Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1719 |
0.434 |
|
| 2016 |
McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, et al. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 27702896 DOI: 10.1073/Pnas.1613601113 |
0.737 |
|
| 2016 |
Gettinger S, Politi K. PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? Clinical Cancer Research. 22: 4539-4541. PMID 27470969 DOI: 10.1158/1078-0432.Ccr-16-1401 |
0.473 |
|
| 2016 |
Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, et al. Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports. PMID 27346347 DOI: 10.1016/J.Celrep.2016.05.087 |
0.564 |
|
| 2016 |
Xia B, Wurtz A, Gettinger SN, Herbst RS, Chiang AC, Wan M, Sklar J, Neumeister V, Politi KA, Goldberg SB. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal of Clinical Oncology. 34: 9049-9049. DOI: 10.1200/Jco.2016.34.15_Suppl.9049 |
0.511 |
|
| 2016 |
Aisner D, Sholl LM, Berry LD, Haura EB, Ramalingam SS, Glisson BS, Socinski MA, Waqar SN, Garon EB, Cetnar JP, Politi KA, Schiller J, Rossi MR, Chen H, Minna JD, et al. Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. Journal of Clinical Oncology. 34: 11510-11510. DOI: 10.1200/Jco.2016.34.15_Suppl.11510 |
0.469 |
|
| 2016 |
Ayeni D, Ho P, Perry C, Kaech S, Politi K. Abstract A083: Modulation of the immune system as a strategy to treat EGFR mutant lung adenocarcinoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A083 |
0.553 |
|
| 2016 |
Raad RA, Walther Z, Gettinger S, Politi K, Puchalski J, Homer R, Cai G. Tumor Genotyping Analysis Using Cytological Specimens of Primary and Metastatic Lung Adenocarcinomas Journal of the American Society of Cytopathology. 5. DOI: 10.1016/J.Jasc.2016.07.122 |
0.459 |
|
| 2015 |
Pirazzoli V, Ayeni D, Meador CB, Sanganahalli B, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26341921 DOI: 10.1158/1078-0432.Ccr-15-0620 |
0.544 |
|
| 2015 |
Morgensztern D, Politi K, Herbst RS. EGFR Mutations in Non-Small-Cell Lung Cancer Find, Divide, and Conquer Jama Oncology. 1: 146-148. PMID 26181013 DOI: 10.1001/Jamaoncol.2014.278 |
0.543 |
|
| 2015 |
Ayeni D, Politi K, Goldberg SB. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26169963 DOI: 10.1158/1078-0432.Ccr-15-1211 |
0.542 |
|
| 2015 |
Politi K, Ayeni D, Lynch T. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell. 27: 751-3. PMID 26058074 DOI: 10.1016/J.Ccell.2015.05.012 |
0.547 |
|
| 2015 |
Politi K, Herbst RS. Lung Cancer in the Era of Precision Medicine Clinical Cancer Research. 21: 2213-2220. PMID 25979927 DOI: 10.1158/1078-0432.Ccr-14-2748 |
0.535 |
|
| 2015 |
Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, et al. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discovery. 5: 534-49. PMID 25735773 DOI: 10.1158/2159-8290.CD-14-0750 |
0.655 |
|
| 2015 |
Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer Research. 75: 1035-45. PMID 25596284 DOI: 10.1158/0008-5472.Can-13-1625 |
0.684 |
|
| 2015 |
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Molecular Cancer Therapeutics. 14: 542-52. PMID 25477325 DOI: 10.1158/1535-7163.Mct-14-0723 |
0.544 |
|
| 2015 |
Bantikassegn A, Song X, Politi K. Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas. American Journal of Respiratory Cell and Molecular Biology. 52: 409-17. PMID 25347711 DOI: 10.1165/Rcmb.2014-0312Ma |
0.467 |
|
| 2015 |
Kris MG, Johnson BE, Kwiatkowski DJ, Wistuba II, Berry LD, Haura EB, Socinski MA, Ramalingam SS, Glisson BS, Waqar SN, Otterson GA, Schiller JH, Garon EB, Cetnar JP, Politi KA, et al. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). Journal of Clinical Oncology. 33: 8094-8094. DOI: 10.1200/Jco.2015.33.15_Suppl.8094 |
0.542 |
|
| 2014 |
Politi K, Gettinger S. Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer Clinical Cancer Research. 20: 5576-5578. PMID 25228532 DOI: 10.1158/1078-0432.Ccr-14-2306 |
0.569 |
|
| 2014 |
Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, ... ... Politi K, et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports. 7: 999-1008. PMID 24813888 DOI: 10.1016/J.Celrep.2014.04.014 |
0.496 |
|
| 2014 |
de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, ... ... Politi K, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discovery. 4: 606-19. PMID 24535670 DOI: 10.1158/2159-8290.Cd-13-0741 |
0.695 |
|
| 2014 |
Lockwood W, Politi K. MYCxing it up with FGFR1 in squamous cell lung cancer. Cancer Discovery. 4: 152-154. PMID 24501305 DOI: 10.1158/2159-8290.Cd-13-1049 |
0.479 |
|
| 2014 |
Pirazzoli V, Politi K. Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse. Csh Protocols. 2014: 178. PMID 24492774 DOI: 10.1101/Pdb.Prot077842 |
0.455 |
|
| 2014 |
Olive KP, Politi K. Translational Therapeutics in Genetically Engineered Mouse Models of Cancer Csh Protocols. 2014: 131-143. PMID 24492770 DOI: 10.1101/Pdb.Top069997 |
0.358 |
|
| 2014 |
Goldberg SB, Narayan A, Carriero NJ, Nemati R, Bommakanti A, Wurtz A, Boffa DJ, Decker RH, Herbst RS, Juergensmeier JM, Politi KA, Gettinger SN, Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma. Journal of Clinical Oncology. 32: 8093-8093. DOI: 10.1200/Jco.2014.32.15_Suppl.8093 |
0.558 |
|
| 2013 |
Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP. DOK2 inhibits EGFR-mutated lung adenocarcinoma. Plos One. 8: e79526. PMID 24255704 DOI: 10.1371/Journal.Pone.0079526 |
0.686 |
|
| 2013 |
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/Gr.152322.112 |
0.512 |
|
| 2013 |
Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discovery. 3: 168-81. PMID 23229345 DOI: 10.1158/2159-8290.Cd-12-0357 |
0.529 |
|
| 2013 |
Lee H, Schaefer G, Heffron T, Malek S, Merchant M, Yauch RL, Pirazzoli V, Politi K, Settleman J. Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M . Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-309 |
0.541 |
|
| 2013 |
Pirazzoli V, Stanchina Ed, Xia J, Zhao Z, Pao W, Politi KA. Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer. Cancer Research. 73: 933-933. DOI: 10.1158/1538-7445.Am2013-933 |
0.603 |
|
| 2013 |
Pirazzoli V, Nebhan C, Song X, Walter Z, Cai G, Wurtz A, Zhao Z, Stanchina EEd, Horn L, Carbone D, Stevens PJ, Miller V, Gettinger S, Pao W, Politi K. Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C90 |
0.617 |
|
| 2013 |
Song X, Fan P, Guha U, Threadgill D, Varmus H, Politi K. Abstract C113: ERBB3 independent activation of the PI3K pathway in EGFR mutant lung adenocarcinomas. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C113 |
0.701 |
|
| 2012 |
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. 2: 922-33. PMID 22956644 DOI: 10.1158/2159-8290.Cd-12-0108 |
0.596 |
|
| 2012 |
Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, ... ... Politi K, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of Clinical Investigation. 122: 2637-51. PMID 22653055 DOI: 10.1172/Jci62058 |
0.518 |
|
| 2012 |
Politi K, Lynch TJ. Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1490-2. PMID 22317760 DOI: 10.1158/1078-0432.Ccr-11-3282 |
0.558 |
|
| 2012 |
Ohashi K, Chmielecki J, Lin Y, Pan H, Vnencak-Jones C, Arcila M, Wang L, Fernandez L, Keisuke A, Shien K, Yamamoto H, Toyooka S, Kiura K, Thomas R, Yang JC, ... ... Politi K, et al. Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer Cancer Research. 72: 1897-1897. DOI: 10.1158/1538-7445.Am2012-1897 |
0.599 |
|
| 2012 |
Sangodkar J, Dhawan N, Melville H, Singh VJ, Farrington C, Yuan E, Rana H, Smith B, Gidwani V, Okrent R, Burstein D, Ohlmeyer M, Politi K, DiFeo A, Narla G. Abstract 1885: Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy Cancer Research. 72: 1885-1885. DOI: 10.1158/1538-7445.Am2012-1885 |
0.554 |
|
| 2012 |
Pirazzoli V, Takezawa K, de Stanchina E, Pao W, Politi K. Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas Clinical Cancer Research. 18: A38-A38. DOI: 10.1158/1078-0432.Mechres-A38 |
0.567 |
|
| 2012 |
Takezawa K, Melnick MA, Riely G, Kris M, Miller V, Ladanyi M, Politi K, Pao W, Pirazzoli V, Song X, Arcila M, De Stanchina E, Ohashi K, Janjigian Y, Spitzler P, et al. Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer Clinical Cancer Research. 18: A23-A23. DOI: 10.1158/1078-0432.Mechres-A23 |
0.592 |
|
| 2012 |
Bruin Ed, Cowell C, Howell M, Varmus H, Politi K, Downward J. Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-A18 |
0.678 |
|
| 2012 |
Politi KA. Abstract IA4: Defining the mechanisms of tumorigenesis by mutant EGFR using mouse models Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.12Aacriaslc-Ia4 |
0.614 |
|
| 2012 |
Song X, Fan P, Guha U, Threadgill D, Varmus H, Politi K. Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR-driven Lung Cancer Clinical Cancer Research. 18: B35-B35. DOI: 10.1158/1078-0432.12Aacriaslc-B35 |
0.677 |
|
| 2011 |
Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 20: 289-99. PMID 21907921 DOI: 10.1016/J.Ccr.2011.08.007 |
0.614 |
|
| 2011 |
Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2273-81. PMID 21263096 DOI: 10.1200/Jco.2010.30.8304 |
0.39 |
|
| 2011 |
Bruin ECd, Cowell CF, Howell M, Varmus HE, Politi K, Downward J. Abstract LB-398: Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-398 |
0.715 |
|
| 2011 |
Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Sage J, Kemp CJ, Varmus HE, Hanash SM. Abstract 3166: Lung cancer bio-signatures in plasma based on the analysis of mouse models Cancer Research. 71: 3166-3166. DOI: 10.1158/1538-7445.Am2011-3166 |
0.6 |
|
| 2010 |
Politi K, Fan PD, Shen R, Zakowski M, Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Disease Models & Mechanisms. 3: 111-9. PMID 20007486 DOI: 10.1242/Dmm.003681 |
0.696 |
|
| 2010 |
McFadden DG, Xuan Z, Rosebrock A, Politi K, Santiago P, Hodges E, Winslow M, Hiramatsu N, Pirun M, Crowley D, Bronson R, Socci N, Varmus H, Hannon G, Jacks T. Abstract LB-151: Targeted gene resequencing in a K-ras-dependent mouse model of metastatic lung adenocarcinoma Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-151 |
0.709 |
|
| 2010 |
Sangodkar J, Katz S, Albano T, Melville H, Burstein D, Politi K, Difeo A, Narla G. Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B41 |
0.572 |
|
| 2009 |
Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/Pnas.0907325106 |
0.482 |
|
| 2009 |
Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. The Journal of Clinical Investigation. 119: 3000-10. PMID 19759520 DOI: 10.1172/Jci38746 |
0.616 |
|
| 2008 |
Zhang Q, Menon R, Deutsch EW, Pitteri SJ, Faca VM, Wang H, Newcomb LF, Depinho RA, Bardeesy N, Dinulescu D, Hung KE, Kucherlapati R, Jacks T, Politi K, Aebersold R, et al. A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biology. 9: R93. PMID 18522751 DOI: 10.1186/Gb-2008-9-6-R93 |
0.44 |
|
| 2008 |
Podsypanina K, Politi K, Beverly LJ, Varmus HE. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proceedings of the National Academy of Sciences of the United States of America. 105: 5242-7. PMID 18356293 DOI: 10.1073/Pnas.0801197105 |
0.601 |
|
| 2007 |
Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Plos Medicine. 4: e294. PMID 17927446 DOI: 10.1371/Journal.Pmed.0040294 |
0.563 |
|
| 2007 |
Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. Plos One. 2: e810. PMID 17726540 DOI: 10.1371/Journal.Pone.0000810 |
0.603 |
|
| 2006 |
Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK, Kim K. BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: S2-7. PMID 17409996 |
0.315 |
|
| 2006 |
Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7232-41. PMID 17189394 DOI: 10.1158/1078-0432.Ccr-06-0658 |
0.531 |
|
| 2006 |
Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America. 103: 9262-7. PMID 16751266 DOI: 10.1073/Pnas.0603371103 |
0.612 |
|
| 2006 |
Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes & Development. 20: 1496-510. PMID 16705038 DOI: 10.1101/Gad.1417406 |
0.702 |
|
| 2006 |
Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Kim K. BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models Journal of Thoracic Oncology. 1: S2-S7. DOI: 10.1016/S1556-0864(15)30002-2 |
0.408 |
|
| 2005 |
Varmus H, Pao W, Politi K, Podsypanina K, Du YCN. Oncogenes come of age Cold Spring Harbor Symposia On Quantitative Biology. 70: 1-9. PMID 16869733 DOI: 10.1101/Sqb.2005.70.039 |
0.598 |
|
| 2005 |
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain Plos Medicine. 2: 0225-0235. PMID 15737014 DOI: 10.1371/Journal.Pmed.0020073 |
0.657 |
|
| 2004 |
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 101: 13306-11. PMID 15329413 DOI: 10.1073/Pnas.0405220101 |
0.691 |
|
| 2004 |
Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Seminars in Cancer Biology. 14: 341-7. PMID 15288259 DOI: 10.1016/J.Semcancer.2004.04.013 |
0.37 |
|
| 2004 |
Kiaris H, Politi K, Grimm LM, Szabolcs M, Fisher P, Efstratiadis A, Artavanis-Tsakonas S. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. The American Journal of Pathology. 165: 695-705. PMID 15277242 DOI: 10.1016/S0002-9440(10)63333-0 |
0.615 |
|
| 2004 |
Politi K, Szabolcs M, Fisher P, Kljuic A, Ludwig T, Efstratiadis A. A mouse model of uterine leiomyosarcoma. The American Journal of Pathology. 164: 325-36. PMID 14695345 DOI: 10.1016/S0002-9440(10)63122-7 |
0.583 |
|
| 2004 |
Politi K, Kljuic A, Szabolcs M, Fisher P, Ludwig T, Efstratiadis A. 'Designer' tumors in mice. Oncogene. 23: 1558-65. PMID 14661057 DOI: 10.1038/Sj.Onc.1207275 |
0.627 |
|
| 2002 |
Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, Morroni M, Cinti S, White MF, Herrera PL, Accili D, Efstratiadis A. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. The Journal of Clinical Investigation. 110: 1011-9. PMID 12370279 DOI: 10.1172/Jci15276 |
0.557 |
|
| Show low-probability matches. |